Confusion dogging best mode requirement in its waning days: Is intentional concealment required?
| June 5, 2013
Ateliers de la Haute-Garonne, and F2C2 Systems SAS v. Broetje Automation USA Inc. and Broetje Automation GMBH
May 21, 2013
Panel: Newman, Prost, and Reyna. Opinion by Newman. Dissent by Prost.
Summary:
An embodiment with three grooves is disclosed in the specification of the patents-in-suit as a preferred embodiment of an apparatus for dispensing rivets. In his deposition one of the two inventors stated that an odd number of grooves was required to prevent a rivet from rotating on itself in the device as a result of the rivet stem going inside one of the grooves. The district court found that the specification did not “state that an odd number of grooves is better than an even number”, and concluded that the patents “effectively conceal the best mode.” Summary judgment is granted. On appeal the CAFC finds no violation of the best mode requirement. Questions: Is the three-groove embodiment the best mode, or is the belief that an odd number of grooves is required the best mode? Has the best mode been concealed, and does the concealment have to be intentional for the patent to be invalidated?
Read More/続きを読む
Public use bar inappropriate when participants in clinical trials do not discern specifics of new product
| May 22, 2013
Dey, L.P. v. Sunovion Pharmaceuticals, Inc.
May 20, 2013
Panel: Bryson, O’Malley, and Newman. Opinion by Bryson. Dissent by Newman.
Summary:
The Federal Circuit reversed and remanded the holding of the District Court that some of Dey’s patents were invalid because a Sunovion’s clinical trial, where Sunovion tested its own product, constituted an invalidating public use. The Federal Circuit determined that although some of test samples were lost and clinical trial was not perfectly confidential, Sunovion’s clinical trial is not an invalidating public use as long as participants do not recognize the specifics of a new drug.
연방지방법원 뉴욕 남부지원(U.S. District Court for the Southern District of New York)은 Sunovion의 임상실험 (clinical trial)이 공용 (public use)에 해당된다고 판단하여, Dey의 특허가 무효 (invalid)라도 판결하였다.
이에 불복하여, 원고는 연방항소법원 (U.S. Court of Appeals for the Federal Circuit)에 상고 (appeal)하였다. 연방항소법원은 임상실험 도중 test sample이 분실되었거나 임상실험이 완벽히 비공개로 진행되지 않았더라도 실험참가자가 신약에 대한 자세한 정보를 모른다면Sunovion의 임상실험은 공용에 해당되지 않는다고 판결하였다.
Tags: anticipation > clinical trial > public use bar > summary judgment > third party use
The Alice in Wonderland En Banc Decision by the Federal Circuit in CLS Bank v. Alice
| May 13, 2013
CLS Bank v. Alice Corporation (en banc)May 10, 2013
After the Federal Circuit issued its en banc decision on May 10, 2013 in CLS Bank v. Alice Corp, the patent owner Alice Corp must be feeling like Alice in Alice in Wonderland, bewildered and frightened by the fantastical situation in which they find themselves:
(1) “bewildered” because an equally divided Federal Circuit affirmed the district court’s holding that Alice’s claimed system to tangible machine components including a first party device, a data storage unit, a second party device, a computer, and a communications controller, programmed with specialized functions consistent with detailed algorithms disclosed in the patent, constitutes a patent ineligible “abstract idea;”
(2) “frightened” because, as Judge Moore puts it, “this case is the death of hundreds of thousands of patents, including all business method, financial system, and software patents as well as many computer implemented and telecommunications patents” (Moore Op. at 2); and
(3) “fantastical” because, as Judge Newman puts it, the en banc court was tasked to provide objective standards for 35 USC §101 patent-eligibility, but instead has “propounded at least three incompatible standards, devoid of consensus, serving to add to the unreliability and cost of the [patent] system…[such that] the only assurance is that any successful innovation is likely to be challenged in opportunistic litigation, whose result will depend on the random selection of the panel” (Newman Op. at 1-2).
Tags: §101 > 101 > abstract ideas > Alice > CLS Bank > computer patents > patent eligibility > patentable subject matter > preemption > software patents
CAFC Reverses Trial Court’s Indefiniteness Ruling
| May 9, 2013
Biosig Instruments v. Nautilus
April 26, 2013
Panel: Wallach, Schall and Newman. Opinion by Wallach. Concurrence by Schall.
Summary
The Court of Appeals for the Federal Circuit rarely finds patent claims to be so indefinite that the they are invalid under 35 U.S.C. § 112, ¶ 2. This historical proclivity was on display last in the CAFC’s decision in Biosig Instruments V. Nautilus. There, the Court reversed a summary judgment of invalidity for indefiniteness, concluding that the claim was “amenable to construction” and not ‘insolubly ambiguous.”
Tags: claim construction > indefiniteness
If Alleged Infringer Doesn’t Cross-Appeal Validity of Narrowly Interpreted Claim, He May Not Challenge Validity of Later Broadly Construed Claim
| May 8, 2013
Lazare Kaplan Int’l, Inc. v. Photoscribe Techs., Inc.,
April 19, 2013
Panel: Lourie, Dyk and Reyna. Opinion by Lourie. Dissent by Dyk.
Summary
Based on narrow claim construction, the district court issued a prior judgment that patent claims were valid but not infringed either literally or under the doctrine of equivalents. Lazare Kaplan (Patentee) appealed the judgment of non-infringement. But Photoscribe (Alleged Infringer) did not cross-appeal the judgment of validity. On appeal, CAFC broadly interpreted the claims and vacated the judgments of no infringement. The issue of infringement was remanded to the district court.
On remand, Photoscribe moved for summary judgment of invalidity based on the CAFC’s broad claim construction, and moved for relief from the district court’s prior judgment of validity under Rule 60(b). The district court granted both of Photoscribe’s motions. Lazare Kaplan appealed. CAFC reversed both district court decisions holding that the district court abused its discretion by granting relief under Rule 60(b).
地裁は、先の判決で、クレームを狭く解釈し、特許クレームは有効だが、侵害はないと判決した。特許権者Lazare Kaplan社は非侵害判決を不服として控訴したが、被疑侵害者Photoscribe社は、特許有効の判決に関して控訴しなかった。控訴審でCAFCはクレームを広く解釈し、非侵害判決を破棄し、地裁に差戻した。
差戻審で、Photoscribe社は、CAFCの解釈に基づいて特許クレームの無効を主張し、一方、特許有効の確定判決に関し、それに拘束されない連邦民事訴訟規則60(b)に基づく救済を求めた。地裁はPhotoscribe社の両方の申立てを認めた。CAFCは地裁が規則60(b)に基づく救済を認めたことは裁量権を逸脱するとし、また、特許クレーム無効判決を破棄した。
Tags: appeal > cross-appeal > rule 60(b)
Clear and Unmistakeable Evidence of a Disclaimer Found in Response to Enablement Rejection
| April 24, 2013
Biogen Idec, Inc., et al. v. GlaxoSmithKline LLC, et al.
April 16, 2013
Panel: Dyk, Plager, Reyna. Opinion by Reyna. Dissent by Plager.
Summary
During prosecution of the patent, applicants responded to the examiner’s enablement rejection, wherein they failed to challenge the examiner’s understanding of the crucial terms, and limited their invention to what the examiner believed their specification enabled. The CAFC affirmed the district court’s narrow claim interpretation of the term “anti-CD20 antibody” based on prosecution history disclaimer.
実施可能要件を満たしていないとして発せられた拒絶通知に対して、出願人は、審査官の理解に対して反論することなく、明細書により実施可能であると審査官が判断したものに発明を限定するような主張を行った。よって、「anti-CD20 antibody」という用語について、狭いクレーム解釈を容認した地裁の判断は誤りでなかったとCAFCは判示した。
Tags: claim construction > disclaimer > estoppel > prosecution disclaimer > prosecution history disclaimer > prosecution history estoppel
Divided Claim Construction Leads to Reversal of Jury Verdict Against Alleged Infringer
| April 17, 2013
Saffran v. Johnson & Johnson
April 4, 2013
Panel: Lourie, Moore, and O’Malley. Opinion by Lourie. Concurrence Opinions by Moore and O’Malley.
Summary
The Federal Circuit reversed a $482 million jury verdict against Cordis, a member of the Johnson & Johnson family. The reversal came as a result of the Federal Circuit’s significant narrowing of the district court’s construction of two key claim limitations. One claim term was narrowed because the Federal Circuit found that the patentee’s arguments made during prosecution of the asserted patent, for the purpose of distinguishing over cited prior art, amounted to prosecution disclaimer. Meanwhile, a structure identified in the specification by the patentee as the corresponding structure to a means-plus-function limitation was disregarded as such, because the specification failed to link the identified structure to the recited function with sufficient specificity.
Tags: claim construction > infringement > means-plus-function > prosecution argument > prosecution disclaimer > prosecution history estoppel
CAFC clarifies the presumption that prior art is enabled after In re Antor Media Corp (Fed. Cir. 2012)
| April 10, 2013
In re Steve Morsa
April 5, 2013
Panel: Rader, Lourie and O’Malley. Opinion by O’Malley.
Summary
The Board of Patent Appeals and Interferences (“Board”) had affirmed an Examiner’s finding that a short press release, relied on for an anticipation rejection, was enabling. In making its decision, the Board had held that arguments alone by the applicant were insufficient to rebut the presumption that a reference was enabling. The CAFC found that the Board and the examiner had failed to engage in a proper enablement analysis of the reference and vacated the anticipation finding.
Tags: affidavit > declaration > declaration and affidavit > enablement > evidence to overcome presumption of enablement > non-enabling prior art > presumption of enablement
CAFC Draws a Line in the Sand as to Adding “Boundary” Lines; PTO recants earlier design practice
| April 3, 2013
In re Owens
March 26, 2013
Panel: Prost, Moore and Wallach. Opinion by Prost.
Summary
Although a practice previously endorsed by the USPTO, the CAFC now holds that the addition of a “boundary” line to a design application constitutes the addition of new matter. Since the parent application gave no indication of one portion of the design being separable from the remainder, the CAFC held that there was no “possession” of the later modification in the original application.
Tags: design > design patents > new matter > possession > written description
Prior Art Reference Must Disclose Arrangement of Elements, Not Merely Each Discrete Element
| March 20, 2013
SynQor, Inc., v. Artesyn Technologies, Inc., et al.
March 13, 2013
Panel: Rader, Lourie and Daniel (Chief District Judge). Opinion by Rader.
Summary
SynQor sued Artesyn Technologies, Inc., and eight other power converter manufactures (Defendants) for infringement of five of SynQor’s U.S. Patents in the United States District Court (“DC”) for the Eastern District of Texas. The DC granted partial summary judgment of infringement of against the Defendants. The DC denied Defendants’ motion for judgment as a matter of law (JMOL) or a new trial after the jury found all asserted claims infringed, not invalid, and awarded lost-profits of $95 million. On appeal, the CAFC affirmed the DC based on a review of the record evidence.
Tags: anticipation > claim construction > ThomasBrown
